Background Little is known concerning the level to which initiation of sildenafil for pulmonary arterial hypertension (PAH) effects patterns of health care usage and costs. and $14,095 during follow-up (sildenafil price during follow-up?=?$5236); distinctive of Gedatolisib PAH-related medicines, however, total health care costs reduced modestly (from $30,104 to $27,605) (p?